Topic: non-small cell lung cancer
Blueprint's data shows its BLU-667 caused some tumor shrinkage in 84% of patients with lung or thyroid cancer.
AstraZeneca will supply fast-growing NSCLC therapy Tagrisso for free in the study, which will see if MP0250 can restore sensitivity to AZ's drug.
AbbVie is abandoning plans to seek out an FDA quick OK for its troubled oncology drug Rova-T in third-line relapsed/refractory small cell lung cancer.
Bristol-Myers Squibb has added Yale Cancer Center to its list of participants in a cancer immunotherapy initiative.
Merck's ERK drug had a low response rate but could be used in combinations for BRAF-mutant cancers.
Bristol-Myers is committing $3.6 billion to a deal that gives Nektar most of the profits and freedom to develop the drug in other combinations.
NIH scientists have modeled the 3D structure of DHHC enzymes, which modify EGFRs, which are implicated in a range of cancers.
The study linked the drug to a 33% disease control rate in NSCLC patients who had previously progressed following treatment with an EGFR inhibitor.
Array and Pfizer's initial focus is to test drug combos in a phase 1b trial in non-small cell lung cancer and pancreatic cancer.
The deal will see Thermo Fisher validate and seek approval for a test to identify RET fusions in non-small cell lung cancer patients.